Latest News

If you are wondering whether Corning’s share price still reflects fair value after a strong run, you are not alone. The stock closed at US$85.23, with returns of 84.3% over 1 year, 156.8% over 3 years and 158.7% over 5 years, although the last 7 days and 30 days saw declines of 6.0% and 9.5% respectively. Recent headlines around Corning have focused on its position in glass and material technologies and how that ties into demand from electronics and communications end markets. This context...

In its latest quarterly update, Packaging Corporation of America reported revenue roughly in line with expectations but earnings per share below analyst forecasts, as management pointed to solid legacy packaging performance alongside ongoing pressure in export containerboard demand. This combination of steady core operations and weaker profitability has sharpened attention on how efficiently the company can convert resilient box demand into earnings. Next, we’ll examine how this...

In early January 2026, Archrock announced that its subsidiary Archrock Services, L.P. priced an upsized private offering of US$800,000,000 in 6.000% senior notes due 2034, with proceeds earmarked to repay a portion of borrowings under its revolving credit facility. This refinancing step reshapes Archrock’s capital structure by extending debt maturities and shifting borrowings from a revolving credit line into longer-term fixed-rate notes. We’ll now examine how issuing US$800,000,000 of...

Hansoh Pharmaceutical Group (SEHK:3692) has just received Chinese NMPA approval to expand lung cancer drug Ameile’s use as a first line option in combination therapy for specific EGFR mutated NSCLC patients. See our latest analysis for Hansoh Pharmaceutical Group. The Ameile update comes after a reshuffle of Hansoh Pharmaceutical Group’s board and committees in late December 2025. The latest 1-day share price return of 2.11% at HK$41.6 sits within a year-to-date share price return of 14.16%...

With no single headline event driving attention, Crane NXT (CXT) is on some investors’ radar after recent price swings, including a 1.2% daily gain and mixed returns over the past 3 months. See our latest analysis for Crane NXT. The recent 1-day share price return of 1.15% and 7-day share price return of 4.71% sit against a 30-day share price return decline of 12.52% and a 90-day share price return decline of 23.78%. Meanwhile, the year to date share price return of 4.71% contrasts with a...

Aveanna Healthcare Holdings (AVAH) has drawn fresh attention after recent research highlighted its value-focused rating and earnings outlook, along with improving revenue trends and guidance that have contributed to a strong share price recovery. See our latest analysis for Aveanna Healthcare Holdings. At a share price of $8.59, Aveanna’s recent moves have come after a strong run, with a year-to-date share price return of 6.31% and a 1-year total shareholder return of 90.47%. The 3-year total...

Moog Inc. recently reached a 52-week high following a run of earnings results that exceeded analyst expectations in each of the past four quarters, while analysts have revised their estimates upward and assigned the company a favorable Zacks Rank of #2 (Buy). Alongside this performance, Moog’s decision to feature its CEO and CFO at the CJS Securities virtual conference highlights management’s intent to spotlight the company’s earnings track record and outlook to a wider institutional...

Global-E Online recently reported that it had become profitable ahead of schedule and was accelerating its expansion in cross-border e-commerce through deeper integration with Shopify and enhanced localization, payments, logistics, and compliance tools. This shift to profitability, combined with its ability to simplify complex taxes, duties, and regulations for merchants, is reinforcing Global-E's role as a key enabler of international direct-to-consumer commerce despite intense competition...

It is usually uneventful when a single insider buys stock. However, When quite a few insiders buy shares, as it...

Forvia has recently announced that Sinopec Capital will take a minority stake in its hydrogen-focused subsidiary, FORVIA Hydrogen Solutions China, through a RMB 300,000,000 (≈ €40,000,000) capital increase, adding an industrial partner across China’s hydrogen value chain. This move gives Forvia a local ally with deep energy and chemical expertise, potentially improving its hydrogen unit’s access to Chinese public and private customers. We’ll now examine how Sinopec Capital’s entry as a local...

PennyMac Financial Services (PFSI) surprised the market with quarterly earnings and revenue that came in ahead of expectations, followed by a wave of more positive analyst outlooks and increased investor interest in the stock. See our latest analysis for PennyMac Financial Services. The strong quarterly result comes after a period of solid momentum, with a 1-day share price return of 6.41% and a 90-day share price return of 24.83%, while the 1-year total shareholder return of 53.66% and...

Altus Group (TSX:AIF) is back in focus after Jones Lang LaSalle renewed and expanded its use of ARGUS Intelligence across global Capital Markets & Investment Services, highlighting fresh commercial traction with a large institutional client. See our latest analysis for Altus Group. Altus Group’s share price has been steady overall this year, with a modest 1 day share price return of 1.67% and a 1 year total shareholder return of 6.56%. This suggests momentum has been relatively muted even as...

Central Japan Railway: Context For Investors With no single headline event driving attention today, Central Japan Railway (TSE:9022) is drawing interest as investors weigh its recent share performance, profitability profile, and revenue trends against the broader Japanese transportation sector. See our latest analysis for Central Japan Railway. Central Japan Railway’s share price, which last closed at ¥4,374, has had modest recent momentum with a 90 day share price return of 2.39%. The 1 year...

If you are wondering whether Jack Henry & Associates is priced fairly or not, this is where we start connecting the share price to what you are actually paying for. The stock last closed at US$189.16, with returns of 6.1% over the past week, 1.1% over the last month, 6.1% year to date, 11.5% over 1 year, 8.3% over 3 years and 30.2% over 5 years. This gives some context for how the market has been reassessing the company. Recent coverage has focused on Jack Henry & Associates as a key player...

XPO recently renewed its long-standing role as the official transportation partner for the Susan G. Komen 3-Day fundraising walks through March 2029, continuing to provide complimentary transport, storage and logistics support for event materials across all route cities. This extended partnership underscores how XPO integrates community engagement into its core logistics capabilities, highlighting the company’s operational reach and brand positioning beyond purely commercial freight...

Merck KGaA (XTRA:MRK) is back in focus after mixed financial updates, with one quarter showing an 11.8% profit decline despite 5.3% net sales growth, and another highlighting 4.7% organic revenue growth and higher EBITDA. See our latest analysis for Merck KGaA. The recent mixed earnings messages seem to align with Merck KGaA’s price action, with a 10.3% 1 month share price return and a 10.5% 3 month share price return contrasting with a 1 year total shareholder return decline of 8.3%. This...

First American Financial (FAF) has drawn investor attention after its recent share moves, with the stock up 2.4% over the past day but down 3.1% over the past month. See our latest analysis for First American Financial. At a share price of $61.49, First American Financial’s recent 1 day share price return of 2.42% sits against a softer 30 day share price return of 3.10%. Its 1 year total shareholder return of 10.36% and 5 year total shareholder return of 37.93% point to steadier progress over...

IAMGOLD’s recent inclusion in the S&P Composite Index has already taken place, marking a significant step in raising its profile among institutional and index-tracking investors in the Canadian market. This index addition can reshape how the company is perceived by larger pools of capital, potentially influencing trading liquidity and investor attention in ways that go beyond its underlying mine performance. With IAMGOLD now part of the S&P Composite Index, we’ll explore how this enhanced...

ING Groep announced in early January 2026 that it will pay a special cash dividend of €0.172 per share on 15 January 2026, funded from a €500 million distribution tied to the up to €1.60 billion shareholder payout plan unveiled on 30 October 2025 and based on 2,902 million ordinary shares outstanding at year-end 2025. This one-off distribution highlights how ING is actively returning excess capital to shareholders, adding a capital-management angle to the broader story of its digital and...

Soho House & Co (SHCO) has recently drawn investor attention after a period of mixed share performance, with the stock showing a small positive 1 year total return alongside negative moves over the past week, month and past 3 months. See our latest analysis for Soho House & Co. The recent 1 day share price return of 2.59% decline, alongside weaker 7 day and 30 day share price returns, suggests fading short term momentum, even as the 3 year total shareholder return of 48.78% points to a...

If you are wondering whether BeOne Medicines is priced for opportunity or already reflecting high expectations, you will want to look closely at what its current valuation is really saying. The stock recently closed at US$337.89, with returns of 8.6% over the last 7 days and 91.2% over the past year, which may signal that the market is reassessing its growth potential or risk profile. Recent coverage around BeOne Medicines has focused on its position within the pharmaceuticals and biotech...

Sino Biopharmaceutical (SEHK:1177) has just reported two key clinical milestones, including first patient enrollment in a Phase III trial for IPF drug candidate TDI01 and positive Phase II data for psoriasis treatment TQH3906. See our latest analysis for Sino Biopharmaceutical. The latest clinical updates arrive after a mixed year for Sino Biopharmaceutical’s shares. The stock has a 7.39% year-to-date share price return at HK$6.83, a 12.44% decline over 90 days, and a very large 1-year total...

If you are wondering whether Procter & Gamble’s current share price offers fair value or not, you are not alone. This article is built to help you size that up clearly. The stock last closed at US$141.87, with returns of 0.1% over 7 days, 1.5% over 30 days, 0.1% year to date, an 8.2% decline over 1 year and 19.3% over 5 years. These figures may have some investors reassessing both its growth potential and risk profile. Recent coverage has focused on Procter & Gamble as a staple name in...

If you are wondering whether Wyndham Hotels & Resorts is attractively priced right now, it helps to first step back and see how the stock has been behaving. The share price closed at US$81.11, with recent returns of 7.8% over 7 days, 7.2% over 30 days, 7.8% year to date and a 17.7% decline over 1 year, alongside gains of 16.7% over 3 years and 45.6% over 5 years. These mixed returns sit against a backdrop of ongoing industry news around travel demand, brand consolidation and competition...